TY - JOUR
T1 - Real-world data of radiofrequency catheter ablation in paroxysmal atrial fibrillation
T2 - Short- and long-term clinical outcomes from the prospective multicenter REAL-AF Registry
AU - REAL-AF Investigators
AU - Osorio, Jose
AU - Miranda-Arboleda, Andres F.
AU - Velasco, Alejandro
AU - Varley, Allyson L.
AU - Rajendra, Anil
AU - Morales, Gustavo X.
AU - Hoyos, Carolina
AU - Matos, Carlos
AU - Thorne, Christopher
AU - D'Souza, Benjamin
AU - Silverstein, Joshua R.
AU - Metzl, Mark D.
AU - Hebsur, Shrinivas
AU - Costea, Alexandru I.
AU - Kang, Steven
AU - Sellers, Matthew
AU - Singh, David
AU - Salam, Tariq
AU - Nazari, Jose
AU - Ro, Alex S.
AU - Mazer, Sean
AU - Moretta, Antonio
AU - Oza, Saumil R.
AU - Magnano, Anthony R.
AU - Sackett, Matthew
AU - Dukes, Jonathan
AU - Patel, Parin
AU - Goyal, Sandeep K.
AU - Senn, Todd
AU - Newton, David
AU - Romero, Jorge E.
AU - Zei, Paul C.
N1 - Publisher Copyright:
© 2024 Heart Rhythm Society
PY - 2024
Y1 - 2024
N2 - Background: The safety and long-term efficacy of radiofrequency (RF) catheter ablation (CA) of paroxysmal atrial fibrillation (PAF) has been well established. Contemporary techniques to optimize ablation delivery, reduce fluoroscopy use, and improve clinical outcomes have been developed. Objective: The purpose of this study was to assess the contemporary real-world practice approach and short and long-term outcomes of RF CA for PAF through a prospective multicenter registry. Methods: Using the REAL-AF (Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation; ClincalTrials.gov Identifier: NCT04088071) Registry, patients undergoing RF CA to treat PAF across 42 high-volume institutions and 79 experienced operators were evaluated. The procedures were performed using zero or reduced fluoroscopy, contact force sensing catheters, wide area circumferential ablation, and ablation index as a guide with a target of 380–420 for posterior and 500–550 for anterior lesions. The primary efficacy outcome was freedom from all-atrial arrhythmia recurrence at 12 months. Results: A total of 2470 patients undergoing CA from January 2018 to December 2022 were included. Mean age was 65.2 ±11.14 years, and 44% were female. Most procedures were performed without fluoroscopy (71.5%), with average procedural and total RF times of 95.4 ± 41.7 minutes and 22.1±11.8 minutes, respectively. At 1-year follow-up, freedom from all-atrial arrhythmias was 81.6% with 89.7% of these patients off antiarrhythmic drugs. No significant difference was identified comparing pulmonary vein isolation vs pulmonary vein isolation plus ablation approaches. The complication rate was 1.9%. Conclusion: Refinement of RF CA to treat PAF using contemporary tools, standardized protocols, and electrophysiology laboratory workflows resulted in excellent short- and long-term clinical outcomes.
AB - Background: The safety and long-term efficacy of radiofrequency (RF) catheter ablation (CA) of paroxysmal atrial fibrillation (PAF) has been well established. Contemporary techniques to optimize ablation delivery, reduce fluoroscopy use, and improve clinical outcomes have been developed. Objective: The purpose of this study was to assess the contemporary real-world practice approach and short and long-term outcomes of RF CA for PAF through a prospective multicenter registry. Methods: Using the REAL-AF (Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation; ClincalTrials.gov Identifier: NCT04088071) Registry, patients undergoing RF CA to treat PAF across 42 high-volume institutions and 79 experienced operators were evaluated. The procedures were performed using zero or reduced fluoroscopy, contact force sensing catheters, wide area circumferential ablation, and ablation index as a guide with a target of 380–420 for posterior and 500–550 for anterior lesions. The primary efficacy outcome was freedom from all-atrial arrhythmia recurrence at 12 months. Results: A total of 2470 patients undergoing CA from January 2018 to December 2022 were included. Mean age was 65.2 ±11.14 years, and 44% were female. Most procedures were performed without fluoroscopy (71.5%), with average procedural and total RF times of 95.4 ± 41.7 minutes and 22.1±11.8 minutes, respectively. At 1-year follow-up, freedom from all-atrial arrhythmias was 81.6% with 89.7% of these patients off antiarrhythmic drugs. No significant difference was identified comparing pulmonary vein isolation vs pulmonary vein isolation plus ablation approaches. The complication rate was 1.9%. Conclusion: Refinement of RF CA to treat PAF using contemporary tools, standardized protocols, and electrophysiology laboratory workflows resulted in excellent short- and long-term clinical outcomes.
KW - Fluoroless
KW - Paroxysmal atrial fibrillation
KW - Procedural outcomes
KW - Pulmonary vein isolation
KW - Radiofrequency catheter ablation
UR - http://www.scopus.com/inward/record.url?scp=85195857737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195857737&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2024.04.090
DO - 10.1016/j.hrthm.2024.04.090
M3 - Article
C2 - 38768839
AN - SCOPUS:85195857737
SN - 1547-5271
JO - Heart Rhythm
JF - Heart Rhythm
ER -